Oxford Brain Diagnostics and Memory Treatment Centers (Bonita Springs and Jacksonville, Florida), establish a research collaboration to explore Alzheimer's disease in subjects who are cognitively impaired and receiving anti-amyloid treatment.

As the global Alzheimer's community enters a new era of drug treatments for Alzheimer's patients, this exploratory project aims to leverage Cortical Disarray Measurement (CDM ® ) as an analytical and reporting tool to assess brain regions impacted by neurodegenerative conditions and quantify the extent of neurodegeneration as measured by the cortical microstructure. OXFORD, England , Sept. 18, 2024 /PRNewswire/ -- Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have established a research collaboration with Memory Treatment Centers.

Working with Dr Don McCarren (DO, FAAN, FAANEM) and Dr Jamie Plante (MD), OBD will investigate cortical microstructural disarray in subjects who are cognitively impaired and receiving an anti-amyloid treatment. We will investigate the use of CDM (from baseline imaging) for the assessment of longitudinal decline in participants who were receiving an anti-amyloid treatment. Dr Steven Chance , CEO, Oxford Brain Diagnostics said 'We are very pleased to be working with Don, Jamie, and the team at MTC.

OBD is fully committed to this collaboration, and we very much look forward to sharing the insights from this project in a research publication as part of our engagement with MTC. Our goal is to continue to push the research boundaries of Alzheimer's disease and showcase the insights that CDM offers in answering the difficult and chall.